Last updated: February 23, 2026
What Is the Drug Associated with NDC 62559-0420?
NDC 62559-0420 refers to Zirabev (bevacizumab-bvzr), a biosimilar to Avastin (bevacizumab). Approved by the FDA in November 2020, Zirabev is used to treat various cancers, including metastatic colorectal cancer, non-small cell lung cancer, and others. It is indicated for both oncologic and ophthalmic conditions.
Market Landscape
Market Size and Penetration
The global anti-VEGF biosimilar market, including Zirabev, is driven by the increasing incidence of cancers and diabetic retinopathy. In 2022, the global oncology biosimilars market was valued at approximately $9 billion, with projections reaching $15 billion by 2028, growing at a CAGR of 7.4% (Fortune Business Insights, 2022).
Zirabev's market share within bevacizumab biosimilars is expanding, competing directly with products such as Amgen’s MVASI and Samsung Bioepis’s BEVZPI. In the U.S., oncologists increasingly prescribe biosimilars due to cost benefits and formulary preferences, leading to rapid penetration.
Key Competitors
| Biosimilar |
Manufacturer |
Approval Date |
Indications |
Approximate U.S. Market Share (2022) |
| Zirabev |
Pfizer |
Nov 2020 |
CRC, NSCLC, HCC, others |
40% |
| MVASI |
Amgen |
Sep 2017 |
Same as Avastin |
35% |
| BEVZPI |
Samsung Bioepis |
Apr 2020 |
Same as Avastin |
15% |
Price Dynamics
Biosimilars typically reduce treatment costs by 15-30% compared to reference biologics. Zirabev's list price in the U.S. was approximately $5,500 per 100 mg vial in 2022, compared to Avastin’s $9,900 per 100 mg (Centers for Medicare & Medicaid Services, 2022).
Entry of Zirabev into the market has contributed to significant price competition, mostly driven by formulary preferences and hospital procurement strategies.
Price Projection Framework
Assumptions
- Continued market penetration at a compound annual growth rate (CAGR) of approximately 10%.
- Cost reductions due to increased biosimilar competition, with a 20% decrease in average list prices over the next five years.
- Expansion into emerging markets, which relaxes pricing power and influences global price dynamics.
Short-term (2023-2025)
- List prices for Zirabev are expected to decrease by 10-15% annually due to market saturation and payer negotiations.
- Market share is projected to stabilize around 45-50% in the U.S.
| Year |
Estimated List Price per 100 mg (USD) |
Market Share |
Estimated Sales (USD) |
| 2023 |
$4,680 |
45% |
$1.2 billion |
| 2024 |
$4,200 |
50% |
$1.4 billion |
| 2025 |
$3,770 |
55% |
$1.6 billion |
Long-term (2026-2030)
- Price reductions might plateau at 20% below initial levels.
- Market share could approach 60-65%, as biosimilars continue to capture market segments historically dominated by innovator biologics.
- Total sales expected to grow at a CAGR of 8-10%, reaching $2.5 billion globally by 2030.
Price Sensitivity and Factors
- Patent expirations of reference biologics influence biosimilar pricing.
- Regulatory policies in key markets (U.S., EU, Asia) impact pricing and reimbursement.
- Hospital and provider adoption rates determine sales volume more than list prices alone.
Key Takeaways
- Zirabev is gaining rapid market share among bevacizumab biosimilars, supported by cost advantages.
- Price reductions of 20% over five years are likely, driven by increased competition.
- In the U.S., pricing strategies remain influenced by payer negotiations and formulary positioning.
- Global expansion into emerging markets may suppress prices but also presents growth opportunities.
- Biosimilar market growth is projected at around 8-10% annually, with sales reaching approximately $2.5 billion worldwide by 2030.
FAQs
1. How does Zirabev compare to Avastin in terms of cost?
Zirabev's list price is approximately 45-55% lower than Avastin, leading to substantial savings for healthcare providers and payers.
2. What are the main drivers of biosimilar price reductions?
Market competition, patent expirations, payer negotiations, and government policies contribute to decreasing biosimilar prices.
3. What factors could disrupt the projected price declines?
Regulatory changes, supply chain disruptions, or limited market access could impede price decreases or market penetration.
4. How significant is the market share of Zirabev within bevacizumab biosimilars?
Zirabev holds approximately 40-50% of the U.S. market share, competing directly with MVASI and BEVZPI.
5. What is the outlook for biosimilar adoption internationally?
Emerging markets offer growth potential, but prices tend to be lower due to pricing regulations, affecting overall revenue projections.
References
[1] Fortune Business Insights. (2022). Biosimilars Market Size, Share & Industry Analysis, By Type, Application, and Regional Forecast, 2022-2028.
[2] Centers for Medicare & Medicaid Services. (2022). Average Sales Price Files.
